Prompt oseltamivir therapy reduces medical care and mortality for patients with influenza infection

Medicine (United States)

Volumn 94, Issue 27, 2015, Pages e1070-

  Wang, Chang Bi ^a   Chiu, Mu Lin ^a,b   Lin, Po Chang ^a,c   Liang, Wen Miin ^a   Chen, Chiu Ying ^a   Chang, Yu Jun ^a,d   Wu, Trong Neng ^a   Wang, Jen Hsien ^c   Sung, Fung Chang ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE; VERY ELDERLY; AGE DISTRIBUTION; ASIAN CONTINENTAL ANCESTRY GROUP; EMERGENCY HEALTH SERVICE; ETHNOLOGY; HOSPITAL PATIENT; INFLUENZA, HUMAN; INSURANCE; OUTPATIENT; RETROSPECTIVE STUDY; SEX RATIO; STATISTICS AND NUMERICAL DATA; TIME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA, HUMAN; INPATIENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OSELTAMIVIR; OUTPATIENTS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TIME FACTORS;

EID: 84941103226     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001070     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Influenza Antiviral Drug Resistance 2013 http://www.cdc.gov/flu/about/qa/antiviralresistance. html Accessed 17 June, 2013
2. WHO. Considerations for assessing the severity of an influenza pandemic. Wkly Epidemiol Rec. 2009; 84: 197-202
3. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2011; 60: 1-24
4. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-Analyses of randomised controlled trials. Brit Med J. 2003; 326: 1235-1240
5. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003; 7: 1-170xi-xiii
6. Yu HJ, Liao QH, Yuan YA, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. Brit Med J. 2010; 341: c4779
7. Lee VJ, Yap J, Cook AR, et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. New Engl J Med. 2010; 362: 2166-2174
8. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003; 163: 1667-1672
9. National Institute for Health and Care Excellence. Influenza-zanamivir, amantadine and oseltamivir (review) (TA168). Technology appraisals TA168 2009 http://guidance.nice.org.uk/TA168/ Accessed 17 June 2013
10. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006; 367: 303-313
11. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza-A randomized controlled trial. J Am Med Assoc. 2000; 283: 1016-1024
12. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza-Randomized controlled trials for prevention and treatment. J Am Med Assoc. 1999; 282: 1240-1246
13. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts-A randomized controlled trial. J Am Med Assoc. 2001; 285: 748-754
14. Smith JR, Dutkowski R. Stockpiling oseltamivir: Roche clarifies data for improved mortality with oseltamivir. Brit Med J. 2005; 331: 1203
15. Parry RL. Japan issues Tamiflu warning after child deaths. 2007; http://www.infowars.net/articles/march2007/210307-b-Tamiflu.htm. Accessed 17 June 2013
16. Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-Analysis of published and unpublished clinical trials. Fam Pract. 2013; 30: 125-133
17. Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Investig. 2003; 23: 561-569
18. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000; 355: 1845-1850
19. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clinical therapeutics. 2007; 29: 2246-2255
20. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007; 23: 2961-2970
21. Sugaya N, Shinjoh M, Mitamura K, et al. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect. 2011; 63: 288-294
22. Lee IK, Liu JW, Wang L, et al. 2009 pandemic Influenza A (H1N1): clinical and laboratory characteristics in pediatric and adult patients and in patients with pulmonary involvement. Influenza Other Respir Viruses. 2012; 6: e152-e161
23. Beigel H, Farrar H, Han AM, et al. Current concepts-Avian influenza A (H5N1) infection in humans. New Engl J Med. 2005; 353: 1374-1385
24. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011; 8: e1001053
25. Chang YM, Li WC, Huang CT, et al. Use of oseltamivir during an outbreak of influenza A in a long-Term care facility in Taiwan. J Hosp Infect. 2008; 68: 83-87
26. Chien YS, Su CP, Tsai HT, et al. Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan. J Infection. 2010; 60: 168-174
27. Aoki FY, Boivin G. Influenza virus shedding; excretion patterns and effects of antiviral treatment. J Clin Virol. 2009; 44: 255-261
28. Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-Analysis. Lancet Infect Dis. 2009; 9: 537-545
29. Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. New Engl J Med. 2009; 361: 2507-2517
30. Yang JR, Lin YC, Huang YP, et al. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009. PloS one. 2011; 6: e18177
31. van der Vries E, Stelma FF, Boucher CAB. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. New Engl J Med. 2010; 363: 1381-1382
32. Yang JR, Huang YP, Lin YC, et al. Early findings of oseltamivirresistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antivir Res. 2010; 88: 256-262